NDAINJECTIONINJECTABLEPriority Review
Approved
Aug 1946
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
2/8 — Basic
Priority Review
SOTRADECOL (sodium tetradecyl sulfate) by Viatris (2) is clinical pharmacology sotradecol (sodium tetradecyl sulfate injection) is a sclerosing agent. First approved in 1946.
Drug data last refreshed 3d ago
Mechanism of Action
CLINICAL PHARMACOLOGY Sotradecol (sodium tetradecyl sulfate injection) is a sclerosing agent. Intravenous injection causes intima inflammation and thrombus formation. This usually occludes the injected vein. Subsequent formation of fibrous tissue results in partial or complete vein obliteration…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Company
Viatris (2)
China - Shanghai
Worked on SOTRADECOL at Viatris (2)? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.